n Diagnosis Age (years) @ start of HD At time of first rtPA infusion No of rtPA Outcomes  (as of 31 Dec 2012)
Age (years) Duration of HD (years) HD Sessions 0.1 mg/kg/h over 1 hour 0.1 mg/kg/h over 2 hours 0.2 mg/kg/h over 1 hour 0.2 mg/kg/h over 2 hours
  1   Renal Dysplasia   2.4   4.9   2.5   390   3   4   2   0 Line remained in-situ x 2.5 years
  2 Bilateral Wilm’s Tumour   2.0   3.1   1.1   171   6   4   30   5 Line remained in-situ x 2 years until transplant
  3 Nephrotic syndrome   10.5   10.8   0.3   47   108   0   0   1 Line remained in-situ x 3.2 years
  4 Posterior Urethral Valves   5.6   6.3   0.7   109   1   0   0   0 Line remained in-situ x 2.1 years until transplant
  5 Renal Dysplasia   14.8   14.9   0.1   15   115   0   0   0 Line remained in-situ x 2.8 years
  6 Primary Hyperoxalosis   0.3   1.7   1.4   218   10   0   22   1 Line remained in-situ x 1.2 years
  7 Prune Belly Syndrome   8.5   9.6   1.1   172   2   0   0   0 Line remained in-situ x 0.75 years until transplant
  8   Renal Dysplasia   0.5   0.9   0.4   62   1   2   10   1 Line remained in-situ x 0.2 years until transplant
  9   Renal Dysplasia   13.9   14.5   0.6   94   2   0   0   0 Line remained in-situ x 0.3 years until transplant
  10 Cystic Kidney Disease HNF1B   4.3   4.7   0.4   63   4   1   4   0 Line remained in-situ x 1 year until transplant
Table 1: Patient age (years) at commencing HD and at time of first rtPA infusion, underlying diagnoses, duration and HD sessions prior to thrombus, doses of rtPA and outcomes.